• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    12/13/22 12:31:21 PM ET
    $ATNF
    $BYSI
    $CLVS
    $HARP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email

    Gainers

    • OpGen (NASDAQ:OPGN) stock increased by 242.3% to $0.43 during Tuesday's regular session. OpGen's stock is trading at a volume of 169.2 million shares as of 12:30 EST. This is 40400.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.9 million.
    • BeyondSpring (NASDAQ:BYSI) shares rose 30.65% to $0.99. Trading volume for BeyondSpring's stock is 3.2 million as of 12:30 EST. This is 2800.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $38.5 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock increased by 22.99% to $0.33. The current volume of 156.3K shares is 77.7% of 180 Life Sciences's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $13.3 million.
    • WAVE Life Sciences (NASDAQ:WVE) shares increased by 22.99% to $4.44. As of 12:30 EST, this security is trading at a volume of 3.5 million shares, making up 946.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $385.8 million.
    • Moderna (NASDAQ:MRNA) stock rose 22.5% to $202.3. The current volume of 17.1 million shares is 365.8% of Moderna's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $77.7 billion.
    • Shuttle Pharmaceuticals (NASDAQ:SHPH) shares increased by 22.26% to $3.13. The current volume of 1.1 million shares is 49.4% of Shuttle Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $42.3 million.

    Losers

    • Quotient (NASDAQ:QTNT) stock declined by 48.9% to $0.35 during Tuesday's regular session. Trading volume for Quotient's stock is 1.3 million as of 12:30 EST. This is 898.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 million.
    • Midatech Pharma (NASDAQ:MTP) stock fell 29.18% to $1.17. As of 12:30 EST, this security is trading at a volume of 93.8K shares, making up 386.1% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 million.
    • Clovis Oncology (NASDAQ:CLVS) stock decreased by 25.27% to $0.15. The current volume of 9.0 million shares is 198.6% of Clovis Oncology's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $21.8 million.
    • Healthcare Triangle (NASDAQ:HCTI) stock decreased by 24.78% to $0.27. Trading volume for this security as of 12:30 EST is 10.7 million, which is 589.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.0 million.
    • Harpoon Therapeutics (NASDAQ:HARP) shares decreased by 23.41% to $1.08. Trading volume for Harpoon Therapeutics's stock is 3.3 million as of 12:30 EST. This is 195.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $35.8 million.
    • Vanda Pharma (NASDAQ:VNDA) stock declined by 23.19% to $8.29. Trading volume for this security as of 12:30 EST is 1.3 million, which is 367.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $469.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ATNF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATNF
    $BYSI
    $CLVS
    $HARP

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Wave Life Sciences Ltd.
    $WVE
    12/12/2025$20.00 → $33.00Outperform
    Wedbush
    Wave Life Sciences Ltd.
    $WVE
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    More analyst ratings

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Moderna with a new price target

    Barclays resumed coverage of Moderna with a rating of Equal Weight and set a new price target of $25.00

    1/28/26 7:18:07 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

    WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER). The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in v

    3/19/26 4:34:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Healthcare Triangle, Inc. Announces Approval of $2 Million Share Repurchase Plan

    PLEASANTON, Calif., March 11, 2026 /CNW/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries, today announces that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $2,000,000 of its outstanding common stock ("2026 Share Repurchase Plan"). The 2026 Share Repurchase Plan was approved by the Company's Board of Directors on March 9, 2026, and became effective immediately. Under the newly authorized plan, the Company may repurchase shares of its common stock from tim

    3/11/26 4:10:00 PM ET
    $HCTI
    EDP Services
    Technology

    Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

    Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced acceptance of a late-breaking oral presentation of data from its ongoing RestorAATion-2 clinical trial of WVE-006, its investigational GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), at the upcoming American Thoracic

    3/5/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    SEC Filings

    View All

    SEC Form DEF 14A filed by Moderna Inc.

    DEF 14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:31:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Moderna Inc.

    DEFA14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:32:27 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Healthcare Triangle Inc.

    8-K - Healthcare Triangle, Inc. (0001839285) (Filer)

    3/11/26 4:30:29 PM ET
    $HCTI
    EDP Services
    Technology

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 10% to 65,782 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/6/26 4:24:57 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 12% to 56,998 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/6/26 4:21:25 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP & General Counsel Williams Timothy sold $350,755 worth of shares (42,434 units at $8.27), decreasing direct ownership by 10% to 377,450 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:54:11 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

    Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif., Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (NASDAQ:ATNF), (the "Company" or "ETHZilla"), has closed its previously announced private placement, raising $425 million in gross proceeds, before placement agent fees and offering expenses (the "Private Placement") through a private investment in public equity transaction ("PIPE") for the purchase and sale of common stock and pre-funded warrants, as applicable, at a purchase

    8/4/25 10:30:00 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT clinical trial for obesity in individuals with higher BMI and comorbidities in 1H 2026, as well as additional trials of WVE-007 as an incretin add-on and as post-incretin maintenance in 2026 Advancing regulatory engagement on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing) for AATD with feedback anticipated mid-2026; RestorAATion-2 clinical trial fully enrolled through 60

    2/26/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026

    CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company's fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the

    2/19/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATNF
    $BYSI
    $CLVS
    $HARP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care